| Patient | Mahalia Jackson |
|---|---|
| Date of birth | 1911-10-26 |
| Identifiers | MRN HR-ML035-SYN-TD; SSN (made up) 000-35-4692 |
| Document date | 2026-11-01 |
| Author | Beatrice Fontenot, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood tests. Concerns: Short of breath on stairs and on stage for about three months, with a dry cough, tiredness and tightness in the chest; she runs out of breath in the middle of long phrases; twice her heart has raced and she felt faint while singing; She was told after an operation twelve years ago that she had sarcoidosis; no record of that operation is available to this clinic, and she wants a clear answer and a plan that a working singer can keep; Her spring concerts and recording sessions are booked; she does not want to cancel unless she has to, and she needs her voice. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning | 40 mg each morning | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks | 30 mg each morning for four weeks | Oral route | 1964-05-11 to 1964-06-08 | completed | S |
| Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks | 20 mg each morning for four weeks | Oral route | 1964-06-08 to 1964-07-06 | completed | S |
| Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks | 15 mg each morning for four weeks | Oral route | 1964-07-06 to 1964-08-03 | completed | S |
| Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning | 10 mg each morning | Oral route | 1964-08-03 to 1964-09-21 | completed | S |
| Prednisone 5 mg oral tablet, one and a half tablets (7.5 mg) by mouth each morning | 7.5 mg each morning | Oral route | 1964-09-21 | active | S |
| Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays | 15 mg once weekly | Oral route | 1964-03-09 to 1964-05-11 | completed | S |
| Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays | 20 mg once weekly | Oral route | 1964-05-11 | active | S |
| Folic acid 1 mg oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food | 1500 mg once daily with food | Oral route | 1964-03-09 to 1964-07-06 | completed | S |
| Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutes | One tablet once weekly | Oral route | 1964-03-16 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-03-09 | active | S |
| Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth daily | One tablet daily | Oral route | 1964-05-11 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Chest radiograph, two views: bilateral symmetric hilar lymph node enlargement with right paratracheal widening and fine reticulonodular opacities in both upper zones; heart size normal; no effusion | 1964-02-09 to 1964-02-09 | completed | S |
| Resting 12-lead ECG: sinus rhythm 84 per minute, PR interval 240 ms (first-degree atrioventricular block), QRS 100 ms, frequent unifocal ventricular ectopic beats; no Q waves; no previous ECG for comparison | 1964-02-09 to 1964-02-09 | completed | S |
| High-resolution CT of the chest: symmetric hilar, subcarinal and right paratracheal lymph nodes up to 2.4 cm, some with fine calcification; perilymphatic micronodules along the bronchovascular bundles and fissures in both upper lobes; no fibrosis, traction bronchiectasis or mass | 1964-02-11 to 1964-02-11 | completed | S |
| Endobronchial ultrasound-guided transbronchial needle aspiration of lymph node stations 4R, 7 and 11L under moderate sedation, with bronchoalveolar lavage: non-necrotizing granulomas at all three stations; acid-fast and fungal stains negative; mycobacterial and fungal cultures sent; lavage lymphocytes 32 percent with a CD4 to CD8 ratio of 5.2; no malignant cells | 1964-02-18 to 1964-02-18 | completed | S |
| Advance care planning conversation, about 30 minutes, including her wishes about the defibrillator | 1964-10-05 to 1964-10-05 | completed | S |
| Full pulmonary function tests (spirometry, lung volumes and diffusing capacity): FVC 74 percent, FEV1 76 percent of predicted, FEV1/FVC 80 percent, total lung capacity 78 percent, DLCO 62 percent of predicted: mild restriction with a reduced diffusing capacity | 1964-02-23 to 1964-02-23 | completed | S |
| 24-hour Holter monitoring: sinus rhythm 58 to 112 per minute; PR interval 230 to 250 ms throughout; ventricular ectopic beats 6 percent of all beats, unifocal; three runs of nonsustained ventricular tachycardia of up to 8 beats; no second- or third-degree atrioventricular block; palpitations recorded during a run of ectopic beats | 1964-02-24 to 1964-02-24 | completed | S |
| Transthoracic echocardiogram: left ventricular ejection fraction 47 percent with thinning and hypokinesis of the basal anteroseptum; normal right ventricle; normal valves; estimated pulmonary artery systolic pressure 28 mmHg; no pericardial effusion | 1964-02-26 to 1964-02-26 | completed | S |
| Cardiac MRI with late gadolinium enhancement: left ventricular ejection fraction 47 percent; patchy mid-wall and subepicardial enhancement of the basal anteroseptum and inferolateral wall (about 9 percent of left ventricular mass), with raised T2 signal in the basal septum; right ventricle normal | 1964-03-03 to 1964-03-03 | completed | S |
| Dilated eye examination by ophthalmology: no anterior or posterior uveitis, no conjunctival nodules, intraocular pressure 15 and 16 mmHg, no cataract | 1964-03-04 to 1964-03-04 | completed | S |
| Cardiac FDG-PET with perfusion imaging, after 72 hours of a high-fat, very-low-carbohydrate diet and an overnight fast: focal FDG uptake in the basal anteroseptum and lateral wall (maximum SUV 6.2) matching the MRI enhancement, with a mild perfusion defect at the same sites; FDG-avid hilar and mediastinal lymph nodes; no uptake elsewhere outside the chest | 1964-03-06 to 1964-03-06 | completed | S |
| Bone density scan (DXA): lumbar spine T-score -1.2, femoral neck T-score -1.6; FRAX adjusted for prednisone of 7.5 mg or more: major osteoporotic fracture 9 percent and hip fracture 1.2 percent at ten years (moderate risk) | 1964-03-16 to 1964-03-16 | completed | S |
| Electrophysiology study: HV interval 58 ms; sustained monomorphic ventricular tachycardia (220 per minute) induced with double extrastimuli from the right ventricular apex, ended by overdrive pacing | 1964-03-18 to 1964-03-18 | completed | S |
| Implantation of a dual-chamber transvenous cardioverter-defibrillator through the left subclavian vein, programmed with ventricular tachycardia therapies and minimal ventricular pacing; enrolled in remote monitoring; no complications | 1964-03-19 to 1964-03-19 | completed | S |
| Repeat spirometry and diffusing capacity after nine weeks of treatment: FVC 84 percent and FEV1 85 percent of predicted, FEV1/FVC 80 percent, DLCO 70 percent of predicted | 1964-05-11 to 1964-05-11 | completed | S |
| Repeat cardiac FDG-PET with the same preparation after five months of treatment: no myocardial FDG uptake; perfusion normal; hilar and mediastinal nodes smaller with low uptake | 1964-08-17 to 1964-08-17 | completed | S |
| Repeat transthoracic echocardiogram: left ventricular ejection fraction 54 percent; basal septal thinning unchanged; normal right ventricle | 1964-08-17 to 1964-08-17 | completed | S |
| Repeat spirometry and diffusing capacity after six months of treatment: FVC 90 percent and FEV1 89 percent of predicted, FEV1/FVC 79 percent, DLCO 76 percent of predicted | 1964-08-24 to 1964-08-24 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1958-11-16 | Tdap vaccine | completed | S |
| 1964-02-09 | Influenza vaccine, this season (inactivated), late in the season | completed | S |
| 1964-03-09 | Pneumococcal conjugate vaccine (PCV20), before immunosuppression | completed | S |
| 1964-03-09 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 1964-03-09 | Hepatitis B vaccine (adjuvanted, two-dose series), dose 1 | completed | S |
| 1964-05-11 | Hepatitis B vaccine (adjuvanted, two-dose series), dose 2 | completed | S |
| 1964-08-24 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 1964-10-05 | Influenza vaccine, this season (inactivated) | completed | S |
| 1964-10-05 | COVID-19 mRNA vaccine, this season's formula | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1952 | Breathlessness and abdominal cramping during a concert tour abroad at 40, with weight loss and a cancelled tour; hysterectomy afterwards, at which granulomas were reported in the abdomen and sarcoidosis was diagnosed; no pathology report available | D (CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died when she was six; cause not recorded in the cited source | D (CLM-0001) |
| Concern | Status | Evidence |
|---|---|---|
| Short of breath on stairs and on stage for about three months, with a dry cough, tiredness and tightness in the chest; she runs out of breath in the middle of long phrases; twice her heart has raced and she felt faint while singing | active | S |
| She was told after an operation twelve years ago that she had sarcoidosis; no record of that operation is available to this clinic, and she wants a clear answer and a plan that a working singer can keep | active | S |
| Her spring concerts and recording sessions are booked; she does not want to cancel unless she has to, and she needs her voice | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 13 on 1964-08-24; Leukocytes [#/volume] in Blood by Automated count 8.1 on 1964-08-24; Lymphocytes [#/volume] in Blood by Automated count 1.4 on 1964-08-24; Platelets [#/volume] in Blood by Automated count 248 on 1964-08-24; Sodium [Moles/volume] in Serum or Plasma 139 on 1964-05-11; Potassium [Moles/volume] in Serum or Plasma 3.9 on 1964-05-11; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 1964-08-24; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M 77 on 1964-08-24; Glucose [Mass/volume] in Serum or Plasma 108 on 1964-08-24; Calcium [Mass/volume] in Serum or Plasma 9.5 on 1964-08-24; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 1964-08-24; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 1964-08-24; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 90 on 1964-08-24; Albumin [Mass/volume] in Serum or Plasma 4.1 on 1964-08-24; Hemoglobin A1c/Hemoglobin.total in Blood 6.2 on 1964-08-24; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 1964-08-24; 1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma 84 on 1964-02-09; Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 96 on 1964-08-24; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1964-02-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1964-02-09; FVC measured/predicted 90 on 1964-08-24; FEV1 measured/predicted 89 on 1964-08-24; FEV1/FVC 79 on 1964-08-24; Diffusion capacity.carbon monoxide/Predicted 76 on 1964-08-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1964-10-05; Cholesterol [Mass/volume] in Serum or Plasma 204 on 1964-10-05; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 1964-10-05; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 126 on 1964-10-05; Triglyceride [Mass/volume] in Serum or Plasma 118 on 1964-10-05 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excluded | resolved | confirmed | R06.09 | S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation. |
| Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked for | resolved | confirmed | R00.2 | S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed. |
| Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raised | resolved | confirmed | E83.52 | S — Synthetic finding; resolved on treatment. |
| Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosis | active | confirmed | D86.2 | S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable). |
| Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolved | resolved | confirmed | J04.0 | S — Synthetic acute infection; not a historical claim. |
| Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heart | active | confirmed | D86.85 | S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R. |
| Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manage | active | confirmed | Z79.52 | S — Synthetic treatment status. |
| Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoring | active | confirmed | Z95.810 | S — Synthetic device status after the synthetic implant. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1964-02-09 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-02-09 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-02-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 1964-02-09 | Platelets [#/volume] in Blood by Automated count | 232 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1964-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1964-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.08 | mg/dL | 0.59-1.04 mg/dL | High | S |
| 1964-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 62 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-02-09 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 1964-02-09 | Calcium [Mass/volume] in Serum or Plasma | 10.8 | mg/dL | 8.6-10.3 mg/dL | High | S |
| 1964-02-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-35 U/L | Normal | S |
| 1964-02-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 8-35 U/L | Normal | S |
| 1964-02-09 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 128 | U/L | 35-104 U/L | High | S |
| 1964-02-09 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-02-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.9 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1964-02-09 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 22 | ng/mL | 30-100 ng/mL | Low | S |
| 1964-02-09 | 1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma | 84 | pg/mL | 18-72 pg/mL | High | S |
| 1964-02-09 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 210 | pg/mL | <=125 pg/mL | High | S |
| 1964-02-09 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 1964-02-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 1964-02-23 | FVC measured/predicted | 74 | % | >=80% | Low | S |
| 1964-02-23 | FEV1 measured/predicted | 76 | % | >=80% | Low | S |
| 1964-02-23 | FEV1/FVC | 80 | % | >=70% | Normal | S |
| 1964-02-23 | Diffusion capacity.carbon monoxide/Predicted | 62 | % | >=80% | Low | S |
| 1964-02-23 | Calcium [Mass/volume] in Serum or Plasma | 10.7 | mg/dL | 8.6-10.3 mg/dL | High | S |
| 1964-02-23 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-02-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 65 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-02-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1964-03-09 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-03-09 | Leukocytes [#/volume] in Blood by Automated count | 4.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-03-09 | Lymphocytes [#/volume] in Blood by Automated count | 0.9 | 10*3/uL | 1-4.8 10*3/uL | Low | S |
| 1964-03-09 | Platelets [#/volume] in Blood by Automated count | 240 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 66 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-03-09 | Glucose [Mass/volume] in Serum or Plasma | 101 | mg/dL | 70-99 mg/dL | High | S |
| 1964-03-09 | Calcium [Mass/volume] in Serum or Plasma | 10.6 | mg/dL | 8.6-10.3 mg/dL | High | S |
| 1964-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-35 U/L | Normal | S |
| 1964-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 8-35 U/L | Normal | S |
| 1964-03-09 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 124 | U/L | 35-104 U/L | High | S |
| 1964-03-09 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-03-09 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 240 | pg/mL | <=125 pg/mL | High | S |
| 1964-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 7 | {score} | S | ||
| 1964-05-11 | Hemoglobin [Mass/volume] in Blood | 13.1 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-05-11 | Leukocytes [#/volume] in Blood by Automated count | 9.8 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-05-11 | Lymphocytes [#/volume] in Blood by Automated count | 1.2 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1964-05-11 | Platelets [#/volume] in Blood by Automated count | 262 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-05-11 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1964-05-11 | Potassium [Moles/volume] in Serum or Plasma | 3.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1964-05-11 | Creatinine [Mass/volume] in Serum or Plasma | 0.92 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-05-11 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 75 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-05-11 | Glucose [Mass/volume] in Serum or Plasma | 118 | mg/dL | 70-99 mg/dL | High | S |
| 1964-05-11 | Calcium [Mass/volume] in Serum or Plasma | 9.6 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1964-05-11 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 31 | U/L | 7-35 U/L | Normal | S |
| 1964-05-11 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 8-35 U/L | Normal | S |
| 1964-05-11 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 96 | U/L | 35-104 U/L | Normal | S |
| 1964-05-11 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-05-11 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.3 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1964-05-11 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 24 | ng/mL | 30-100 ng/mL | Low | S |
| 1964-05-11 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 140 | pg/mL | <=125 pg/mL | High | S |
| 1964-05-11 | FVC measured/predicted | 84 | % | >=80% | Normal | S |
| 1964-05-11 | FEV1 measured/predicted | 85 | % | >=80% | Normal | S |
| 1964-05-11 | FEV1/FVC | 80 | % | >=70% | Normal | S |
| 1964-05-11 | Diffusion capacity.carbon monoxide/Predicted | 70 | % | >=80% | Low | S |
| 1964-05-11 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1964-08-24 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 12-15.5 g/dL | Normal | S |
| 1964-08-24 | Leukocytes [#/volume] in Blood by Automated count | 8.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1964-08-24 | Lymphocytes [#/volume] in Blood by Automated count | 1.4 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1964-08-24 | Platelets [#/volume] in Blood by Automated count | 248 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1964-08-24 | Creatinine [Mass/volume] in Serum or Plasma | 0.9 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1964-08-24 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1959)/1.73 sq M | 77 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1964-08-24 | Glucose [Mass/volume] in Serum or Plasma | 108 | mg/dL | 70-99 mg/dL | High | S |
| 1964-08-24 | Calcium [Mass/volume] in Serum or Plasma | 9.5 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 1964-08-24 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 29 | U/L | 7-35 U/L | Normal | S |
| 1964-08-24 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 8-35 U/L | Normal | S |
| 1964-08-24 | Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 90 | U/L | 35-104 U/L | Normal | S |
| 1964-08-24 | Albumin [Mass/volume] in Serum or Plasma | 4.1 | g/dL | 3.5-5 g/dL | Normal | S |
| 1964-08-24 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.2 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetes | High | S |
| 1964-08-24 | 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma | 34 | ng/mL | 30-100 ng/mL | Normal | S |
| 1964-08-24 | Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma | 96 | pg/mL | <=125 pg/mL | Normal | S |
| 1964-08-24 | FVC measured/predicted | 90 | % | >=80% | Normal | S |
| 1964-08-24 | FEV1 measured/predicted | 89 | % | >=80% | Normal | S |
| 1964-08-24 | FEV1/FVC | 79 | % | >=70% | Normal | S |
| 1964-08-24 | Diffusion capacity.carbon monoxide/Predicted | 76 | % | >=80% | Low | S |
| 1964-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1964-10-05 | Cholesterol [Mass/volume] in Serum or Plasma | 204 | mg/dL | <=200 mg/dL | High | S |
| 1964-10-05 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=50 mg/dL | Normal | S |
| 1964-10-05 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 126 | mg/dL | <=129 mg/dL | Normal | S |
| 1964-10-05 | Triglyceride [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=149 mg/dL | Normal | S |
| 1964-10-05 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1964-02-09 | Body height | 170 | cm | S |
| 1964-02-09 | Body weight | 92 | kg | S |
| 1964-02-09 | Body mass index (BMI) [Ratio] | 31.8 | kg/m2 | S |
| 1964-02-09 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1964-02-09 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1964-02-09 | Heart rate | 86 | /min | S |
| 1964-02-09 | Respiratory rate | 18 | /min | S |
| 1964-02-09 | Body temperature | 36.8 | Cel | S |
| 1964-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1964-02-23 | Body height | 170 | cm | S |
| 1964-02-23 | Body weight | 91.6 | kg | S |
| 1964-02-23 | Body mass index (BMI) [Ratio] | 31.7 | kg/m2 | S |
| 1964-02-23 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1964-02-23 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1964-02-23 | Heart rate | 82 | /min | S |
| 1964-02-23 | Respiratory rate | 18 | /min | S |
| 1964-02-23 | Body temperature | 36.7 | Cel | S |
| 1964-02-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1964-03-09 | Body height | 170 | cm | S |
| 1964-03-09 | Body weight | 91.2 | kg | S |
| 1964-03-09 | Body mass index (BMI) [Ratio] | 31.6 | kg/m2 | S |
| 1964-03-09 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1964-03-09 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1964-03-09 | Heart rate | 80 | /min | S |
| 1964-03-09 | Respiratory rate | 18 | /min | S |
| 1964-03-09 | Body temperature | 36.6 | Cel | S |
| 1964-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| 1964-05-11 | Body height | 170 | cm | S |
| 1964-05-11 | Body weight | 94 | kg | S |
| 1964-05-11 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 1964-05-11 | Systolic blood pressure | 138 | mm[Hg] | S |
| 1964-05-11 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 1964-05-11 | Heart rate | 66 | /min | S |
| 1964-05-11 | Respiratory rate | 16 | /min | S |
| 1964-05-11 | Body temperature | 36.6 | Cel | S |
| 1964-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1964-08-24 | Body height | 170 | cm | S |
| 1964-08-24 | Body weight | 93 | kg | S |
| 1964-08-24 | Body mass index (BMI) [Ratio] | 32.2 | kg/m2 | S |
| 1964-08-24 | Systolic blood pressure | 130 | mm[Hg] | S |
| 1964-08-24 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1964-08-24 | Heart rate | 64 | /min | S |
| 1964-08-24 | Respiratory rate | 16 | /min | S |
| 1964-08-24 | Body temperature | 36.7 | Cel | S |
| 1964-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1964-06-15 | Body height | 170 | cm | S |
| 1964-06-15 | Body weight | 93.4 | kg | S |
| 1964-06-15 | Body mass index (BMI) [Ratio] | 32.3 | kg/m2 | S |
| 1964-06-15 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1964-06-15 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1964-06-15 | Heart rate | 72 | /min | S |
| 1964-06-15 | Respiratory rate | 16 | /min | S |
| 1964-06-15 | Body temperature | 37.4 | Cel | S |
| 1964-06-15 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1964-10-05 | Body height | 170 | cm | S |
| 1964-10-05 | Body weight | 92.2 | kg | S |
| 1964-10-05 | Body mass index (BMI) [Ratio] | 31.9 | kg/m2 | S |
| 1964-10-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1964-10-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1964-10-05 | Heart rate | 66 | /min | S |
| 1964-10-05 | Respiratory rate | 16 | /min | S |
| 1964-10-05 | Body temperature | 36.7 | Cel | S |
| 1964-10-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1964-02-09 | Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood tests | finished | S |
| 1964-02-23 | EBUS result: sarcoidosis; pulmonology consultation, lung function, screening for other organ involvement, and cardiac tests | finished | S |
| 1964-03-09 | Cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referral | finished | S |
| 1964-05-11 | Nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedule | finished | S |
| 1964-08-24 | Six months of treatment: repeat FDG-PET, steroid taper, and plans for touring | finished | S |
| 1964-06-15 | Same-day sick visit for laryngitis on immunosuppressive treatment | finished | S |
| 1964-10-05 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Pulmonology (sarcoidosis) consultation within two weeks, with EBUS-guided lymph node sampling arranged directly from the referral, to confirm the diagnosis and plan treatment | completed | GL-ATS-SARC-2020, GL-ERS-SARC-2021 | S |
| Diagnosis of suspected sarcoidosis: chest radiograph and CT of the chest, tissue by EBUS-guided needle aspiration rather than mediastinoscopy, stains and cultures for mycobacteria and fungi, an interferon-gamma release assay and HIV test to exclude other causes; serum ACE is not used to make or exclude the diagnosis | completed | GL-ATS-SARC-2020 | S |
| Screening every patient with suspected sarcoidosis for other organ involvement: ECG, serum calcium with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, creatinine, liver tests and alkaline phosphatase, complete blood count, TSH, and an eye examination; stop the calcium and vitamin D supplement while calcium is high | completed | GL-ATS-SARC-2020 | S |
| Cardiac evaluation for suspected cardiac sarcoidosis (abnormal ECG and palpitations): 24-hour Holter monitoring, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with a dietary preparation, all before glucocorticoids begin; cardiology and electrophysiology review | completed | GL-HRS-CS-2014, GL-AHA-CS-2024, GL-ATS-SARC-2020 | S |
| Treatment of cardiac and pulmonary sarcoidosis: prednisone 40 mg daily, tapered over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly (increased to 20 mg) and folic acid, continued for at least a year for cardiac disease; repeat FDG-PET after about six months | completed | GL-ERS-SARC-2021, GL-AHA-CS-2024, GL-HRS-CS-2014 | S |
| Methotrexate safety: hepatitis B and C screening before starting, blood count, liver tests and creatinine every two to four weeks for the first three months and then every eight to twelve weeks, no alcohol, and no trimethoprim-sulfamethoxazole while on methotrexate | completed | GL-ACR-DMARD-2012, GL-ERS-SARC-2021 | S |
| Glucocorticoid protection: bone density scan and FRAX, alendronate weekly, dietary calcium only (no supplements while calcium was high), vitamin D replaced cautiously once calcium is normal, with calcium rechecked; atovaquone pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate; glucose, blood pressure, weight, mood, sleep and eye pressure checks | completed | GL-ACR-GIOP-2022, GL-CMID-2026, GL-ERS-SARC-2021 | S |
| Vaccination before immunosuppression: PCV20, recombinant zoster vaccine, hepatitis B vaccine for a non-immune adult, influenza and COVID-19 vaccines; no live vaccines while on prednisone and methotrexate | completed | GL-CDC-IMZ-2026 | S |
| Arrhythmia risk: metoprolol for ventricular ectopy; electrophysiology study for a left ventricular ejection fraction above 35 percent with scar on MRI and nonsustained ventricular tachycardia, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced; remote device monitoring, including on tour | completed | GL-HRS-CS-2014, GL-AHA-CS-2024 | S |
| Performing and travel: concerts paused until the defibrillator wound has healed and the first device check is done, then a lighter schedule with rest days, voice care, and a travel letter with her device card and medicine list; no driving for one week after the implant | completed | GL-HRS-CS-2014, GL-ERS-SARC-2021 | S |
| Depression screening at each phase, plain explanations with written information, and support she chooses; she decides who receives each note | completed | GL-USPSTF-DEP-2023 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation | 1964-03-09 | completed | EBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeks | S |
| Calcium in the normal range within three months | 1964-05-11 | completed | Calcium 9.6 mg/dL after nine weeks of treatment | S |
| FVC and DLCO improved by at least 10 percent of predicted within six months | 1964-08-24 | completed | FVC 74 to 90 percent and DLCO 62 to 76 percent of predicted | S |
| No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better | 1964-08-24 | completed | Myocardial uptake resolved; ejection fraction 54 percent from 47 | S |
| Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent | 1964-08-24 | completed | Prednisone 10 mg at six months and tapering | S |
| Back on stage with a schedule she can sustain, with her voice protected | 1964-08-24 | completed | Two concerts a week since late spring; a longer autumn tour planned | S |